Table 1.
Demographic and disease characteristics of patients receiving the same treatment at vaccination and at 1
| RA (n = 163) | SpA (n = 139) | |||||
|---|---|---|---|---|---|---|
| Treatment group | MTX monotherapy | Anti-TNF monotherapy | Anti-TNF + MTX | Anti-TNF monotherapy | Anti-TNF + MTX | NSAID/analgesics |
| Number of patients at vaccination | 85 | 79 | 89 | 83 | 83 | 86 |
| Number (%) of patients remaining on original therapy at 1.5-year follow-up | 57 (67%) | 50 (63%) | 56 (63%) | 47 (47%) | 49 (59%) | 43 (50%) |
| Age, mean (SD); years | 63.5 (11) | 59.9 (14) | 60.5 (9) | 50.3 (12) | 51.6 (11) | 52.8 (12) |
| Female (%) | 77% | 90% | 75% | 38% | 57% | 49% |
| Disease duration, mean (SD); years | 12.6 (10) | 19.8 (11) | 16.8 (11) | 16.8 (11) | 13.1 (10) | 13.6 (12) |
| RF positive (%) | 81 | 86 | 84 | - | - | - |
| Anti-CCP positive (%) | 77 | 76 | 88 | - | - | - |
| HLA B27 positive (%) | - | - | - | 53 | 33 | 63 |